A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Summary

The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).

Timeline

Start

2020-07-07

Primary completion

2023-12-21

Completion

2023-12-21

Publications

• Inacio Cazeiro D, Azaredo Raposo M, Guimaraes T, Lousada N, Jenkins D, R Inacio J, Moreira S, Mineiro A, Freitas C, Martins S, Ferreira R, Luis R, Cardim N, Pinto FJ, Placido R. Chronic thromboembolic pulmonary hypertension: A comprehensive review of pathogenesis, diagnosis, and treatment strategies. Rev Port Cardiol. 2025 Feb;44(2):121-137. doi: 10.1016/j.repc.2024.04.006. Epub 2024 Jun 28. English, Portuguese.

Drugs

Indications